Canaloplasty

Canaloplasty is a nonpenetrating glaucoma procedure designed to improve aqueous humor outflow through Schlemm’s canal and the eye’s natural drainage pathways. It is used primarily in the management of open-angle glaucoma, with patient selection influenced by disease severity, angle anatomy, prior procedures, medication burden, and surgeon experience. Unlike filtering surgery, canaloplasty generally seeks to preserve the eye’s external tissue barriers and reduce reliance on an implanted drainage device.

The procedure is evolving alongside broader efforts to reduce dependence on topical medications while limiting complications associated with more invasive filtration approaches. Adoption is shaped by refinements in catheter-based and viscodilation techniques, the growing role of minimally invasive glaucoma surgery, improved intraoperative visualization, and the use of canaloplasty in combination with cataract surgery. Clinical decision-making remains individualized because pressure-lowering requirements, anatomical suitability, and the need for rapid or substantial pressure reduction differ across patients.

Artificial intelligence can support canaloplasty pathways by identifying progression patterns in optical coherence tomography, visual-field testing, and anterior-segment imaging. Predictive models may help clinicians distinguish patients likely to benefit from angle-based or Schlemm’s canal procedures from those requiring more aggressive pressure-lowering strategies. AI can also assist with postoperative monitoring, adherence assessment, risk stratification, and detection of subtle structural change. Its clinical value depends on representative training data, transparent validation, interoperability with ophthalmic systems, and clinician oversight rather than automated replacement of surgical judgment.

In North America, canaloplasty development is supported by specialized glaucoma services, ambulatory surgical infrastructure, and clinician familiarity with procedure-based treatment pathways. Europe places strong emphasis on evidence generation, health-system evaluation, and standardized clinical practice, while Asia-Pacific combines advanced ophthalmic centers with substantial unmet needs and uneven access across countries. Latin America is influenced by differences in reimbursement, specialist concentration, and availability of modern surgical equipment. The Middle East is characterized by investment in tertiary healthcare and referral centers, whereas Africa faces wider constraints in screening, specialist availability, continuity of care, and surgical capacity. Across all regions, training, postoperative follow-up, and affordability remain important determinants of real-world use.

ASEAN markets show varied healthcare capacity, regulatory environments, and access to glaucoma specialists, making regional harmonization and training important. BRICS countries combine large and diverse patient populations with differing levels of public and private ophthalmic infrastructure. The European Union benefits from regulatory coordination and cross-border clinical knowledge exchange, although reimbursement and national adoption decisions remain country-specific. G7 systems generally have advanced surgical capabilities but face scrutiny over clinical value, workforce efficiency, and healthcare expenditure. GCC countries are supported by concentrated investment in specialist care, while NATO members span highly different health systems and procurement structures; alliance membership alone does not determine canaloplasty access or clinical uptake.

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States have established ophthalmic specialties and access to advanced glaucoma evaluation, although reimbursement, guideline preferences, and surgeon training vary. China and India combine significant glaucoma-care needs with rapid development of tertiary ophthalmology and uneven access between major cities and rural areas. Brazil and Mexico face regional disparities in specialist availability, public-sector capacity, and continuity of follow-up. Russia’s adoption environment is shaped by healthcare-system structure, specialist distribution, and access to equipment and training. Across these countries, patient selection, local evidence, procurement pathways, and postoperative monitoring are central to sustainable use.

Leaders should prioritize prospective evidence that compares canaloplasty with established medical, laser, and surgical alternatives across clearly defined glaucoma subgroups. Training programs should emphasize angle anatomy, complication management, patient counseling, and postoperative pressure control. Health systems can improve outcomes by integrating imaging, medication history, visual-field data, and longitudinal follow-up into treatment pathways. Device and service strategies should account for local reimbursement, operating-room capabilities, maintenance requirements, and equitable access. AI initiatives should be governed through clinical validation, privacy safeguards, bias testing, and clear accountability for decisions.

This executive summary uses a structured qualitative framework focused on canaloplasty’s clinical role, procedural evolution, enabling technologies, regional conditions, group-level healthcare characteristics, and country-specific access factors. The analysis distinguishes established clinical concepts from forward-looking opportunities and avoids unsupported numerical claims. Insights are organized through cross-market comparison of glaucoma-care infrastructure, specialist availability, regulatory and reimbursement context, surgical training, technology readiness, and continuity of postoperative care. Country and group observations are presented as contextual interpretations rather than measures of market size, share, or growth.

Canaloplasty occupies an important role within the broader movement toward tissue-sparing glaucoma intervention. Its practical value will depend less on procedural novelty alone than on appropriate patient selection, durable pressure control, surgeon expertise, reliable follow-up, and integration with imaging and medication-management systems. Regional and country conditions will continue to influence access, while responsible AI may improve assessment and monitoring. Industry and healthcare leaders that combine rigorous evidence with training, affordability, and accountable technology adoption will be best positioned to support clinically meaningful use.